

RESEARCH ARTICLE

Open Access

Determination of circulating *Mycobacterium* tuberculosis strains and transmission patterns among pulmonary TB patients in Kawempe municipality, Uganda, using MIRU-VNTR

Lydia Nabyonga^{1†}, David P Kateete¹, Fred A Katabazi¹, Paul R Odong¹, Christopher C Whalen², Katherine R Dickman^{1,3†} and Joloba L Moses^{1*}

Abstract

Background: Mycobacterial interspersed repetitive units - variable number of tandem repeats (MIRU-VNTR) genotyping is a powerful tool for unraveling clonally complex *Mycobacterium tuberculosis* (MTB) strains and detection of transmission patterns. Using MIRU-VNTR, MTB genotypes and their transmission patterns among patients with new and active pulmonary tuberculosis (PTB) in Kawempe municipality in Kampala, Uganda was determined.

Results: MIRU-VNTR genotyping was performed by PCR-amplification of 15 MTB-MIRU loci from 113 cultured specimens from 113 PTB patients (one culture sample per patient). To determine lineages, the genotypes were entered into the MIRU-VNTR*plus* database [http://www.miru-vntrplus.org/] as numerical codes corresponding to the number of alleles at each locus. Ten different lineages were obtained: Uganda II (40% of specimens), Uganda I (14%), LAM (6%), Delhi/CAS (3%), Haarlem (3%), Beijing (3%), Cameroon (3%), EAI (2%), TUR (2%) and S (1%). Uganda I and Uganda II were the most predominant genotypes. Genotypes for 29 isolates (26%) did not match any strain in the database and were considered unique. There was high diversity of MIRU-VNTR genotypes, with a total of 94 distinct patterns. Thirty four isolates grouped into 15 distinct clusters each with two to four isolates. Eight households had similar MTB strains for both index and contact cases, indicating possible transmission.

Conclusion: MIRU-VNTR genotyping revealed high MTB strain diversity with low clustering in Kawempe municipality. The technique has a high discriminatory power for genotyping MTB strains in Uganda.

Background

Tuberculosis (TB) is a leading cause of morbidity and mortality throughout sub-Saharan Africa, and Uganda ranks sixteenth among countries with the highest burden of disease [1]. Co-infection with HIV/AIDS and the emergence of multi-drug resistant (MDR) *Mycobacterium tuberculosis* (MTB) strains have made TB a major public health problem [2]. The incidence of TB in Uganda is estimated at 330 cases per 100,000 persons per year, and this includes both HIV infected and non-

HIV infected patients [3]. TB prevalence in Uganda is believed to be higher than reported due to lack of sufficient healthcare; indeed, many people are not aware that they are infected with MTB and this has led to low levels of diagnosis and treatment [4]. Uganda also has one of the lowest TB cure rates (32%) and high drug default rate [1], which may lead to an increase in drug resistance mutations.

Molecular genotyping tools for MTB such as *IS*6110-based restriction fragment length polymorphism (RFLP), "regions of difference" (RD) analysis, spoligotyping, MIRU-VNTR, and single nucleotide polymorphism (SNP) analysis have become invaluable in TB diagnosis and investigations of disease transmission dynamics, outbreaks and phylogenetics [5,6]. Of the MTB

¹Department of Medical Microbiology, School of Biomedical Sciences, Makerere University College of Health Sciences, Kampala, Uganda Full list of author information is available at the end of the article



^{*} Correspondence: moses.joloba@case.edu

[†] Contributed equally

genotyping tools, the gold standard is IS6110-RFLP, a laborious method that requires large amounts of DNA per isolate, and has poor inter-laboratory reproducibility [7]. MIRU-VNTR, a faster genotyping method with discriminatory power higher than that of IS6110 RFLP, has recently been introduced [7,8]. MIRU-VNTR genotyping is performed by amplifying a panel of 12, 15 or 24 loci [9]; genotyping with a panel of 15 loci is best suited for epidemiologic studies [7,10]. Additionally, MIRU-VNTR can detect mixed MTB strains in a single sputum sample [7,11]. Due to its portable data format, MIRU-VNTR can be used as a multi-purpose tool for strain identification using a reference database [2]. However, the choice of appropriate loci for MIRU-VNTR requires evaluation in diverse MTB lineages in countries with high TB prevalence [7]. Mixed MTB infections in Ugandan patients with pulmonary TB (PTB) were recently reported using MIRU-VNTR [11], but genotypes/strains for the entire patient population were not determined. In this study, we aimed to determine the distribution and diversity of MTB lineages in Kawempe municipality using MIRU-VNTR genotyping, and assess the ability of the technique to discriminate the predominant genotypes and detect transmission in this community.

Methods

Patients, sample processing and cultures

This study was approved by the Joint Clinical Research Centre (JCRC) Institutional Review Board (Kampala, Uganda) and the University Hospitals Cleveland Institutional Review Board (Cleveland, Ohio). Informed written consent was obtained from patients who participated. Sputum samples were collected from patients with at least one positive culture for MTB, who were previously enrolled in the Kawempe Community Household Contact Study, an ongoing epidemiological study in Kampala, Uganda, from which several papers have been published [12-15]. Samples were collected consecutively from October 2007 through February 2009, from patients with PTB symptoms who reported not having received treatment for TB in the preceding month. Patient demographics, sample processing and cultures, drug susceptibility testing and DNA extraction are described in Dickman et al, 2010 [11]. Cultures were confirmed as MTB by PCR-detection of a 500 bp fragment of the IS6110, which is common in the members of the MTB complex [16].

MIRU-VNTR PCR and data analysis

MIRU-VNTR genotyping was performed by PCR-amplification of a panel of 15 MTB MIRU loci using primers described in the MIRU-VNTR standard protocol [8,11,17]. To size amplicons, gel (3% agarose in TBE) electrophoresis for three hours at 120 constant voltage

was performed. The allele calling table in the Supply protocol [8,17] was used to assign the number of alleles corresponding to the amplicon sizes. To determine MTB strain lineages, relatedness or clustering, the MIRU-VNTR genotypes (see additional file 1) were matched with reference strains in the MIRU-VNTR plus database (http://www.miru-vntrplus.org/), using a categorical coefficient of 1 and a distance cut off of < 0.3 that corresponds to a seven locus difference. Then, a Neighbor Joining dendrogram was constructed from the strains' genotypes using the MIRU-VNTR plus online program, on assumption of different evolutionary rates (molecular clocks) for MTB MIRU loci [9].

A cluster was defined as two or more patients' strains with identical genetic patterns. Clusters were assumed to have arisen from recent transmission, and the clustering rate was used to determine recent transmission of MTB [18]. The minimum estimate of the proportion of TB cases related to recent transmission was calculated using the formula: (number of clustered patients - number of clusters)/total number of patients [18]. To determine the discriminatory power of MIRU-VNTR for this patient population, the Hunter Gaston Discriminatory Index (HGDI) [19] was calculated.

Results and Discussion

High strain diversity in Kawempe municipality

Between October 2007 and May 2009, 113 MTB cultures from 113 patients with PTB were genotyped with MIRU-VNTR using a panel of 15 loci [11]. Ten distinct strains were identified; EAI, Delhi/CAS, Uganda I, Uganda II, LAM, Haarlem, S, Beijing, Cameroon and TUR. Isolates from 29 (26%) patients did not match any strain in the database and were regarded unique (see Table 1). These findings agree with a previous study [20], which found strains of different lineages including Delhi/CAS, LAM and Beijing in Rubaga municipality,

Table 1 Distribution of MTB lineages

| Dakianta N. 112 | | | | | | | | | |
|-------------------|------------|--|--|--|--|--|--|--|--|
| Patients, N = 113 | | | | | | | | | |
| Lineage/strain | Number (%) | | | | | | | | |
| Uganda I | 16 (14) | | | | | | | | |
| Uganda II | 45 (40) | | | | | | | | |
| LAM | 6 (5) | | | | | | | | |
| Beijing | 3 (3) | | | | | | | | |
| Dehli/CAS | 3 (3) | | | | | | | | |
| Haarlem | 3 (3) | | | | | | | | |
| Cameroon | 3 (3) | | | | | | | | |
| TUR | 2 (2) | | | | | | | | |
| EAI | 2 (2) | | | | | | | | |
| S | 1 (1) | | | | | | | | |
| Unique | 29 (26) | | | | | | | | |




Figure 1 Neighbor joining dendrogram showing clustering among the genotyped MTB strains. The 15 clusters are indicated with a numerical brown font. The order of MIRU loci is as follows, left to right: 424, 577, 580, 802, 960, 1644, 1955, 2163b, 2165, 2401, 2996, 3192, 3690, 4952 and 4150.

Uganda, using RD genotyping. Furthermore, in this study, Uganda I and Uganda II were the predominant lineages (at 14% and 40% prevalence, respectively), followed by LAM (5%). An earlier study using RD genotyping reported MTB "Uganda genotype" as the predominant strain in Rubaga municipality [21]. The Beijing, Dehli/CAS, Haarlem and Cameroon strains were individually found in only 3% of the patients. One MDR strain was unique while two with mono-resistance to isoniazid were of EAI lineage. Another strain with mono-resistance to streptomycin was unique.

There is high genetic diversity in Kawempe Municipality; the HGDI [19] was 0.996, which is very high and comparable to that of Mulenga et al (0.988) in Ndola, Zambia [22], an urban setting in an endemic country similar to Uganda. The high genetic diversity of MTB strains in Kawempe community could be a consequence of reactivation of latent MTB infection, increased human population/global travel and diversity in host genetics [23].

MIRU-VNTR patterns

There was high diversity of MIRU-VNTR patterns among the characterized isolates; a total of 94 distinct

patterns were identified, which included 15 clusters each with two to four isolates. In total 34 (30%) isolates clustered while 79 (70%) had unique patterns (see Figure 1). The clustering rate was 17%, implying that the minimum estimate of disease related to recent transmission was 17% (see methods). This is low considering the high population density, endemicity, poor housing and HIV/ AIDS prevalence in Kawempe municipality [4], which are risk factors for TB transmission. Similar to the Casablanca study [18], most disease in this community could be due to reactivation of MTB infection rather than recent transmission. Furthermore, the clustering rate was low in comparison with an earlier study in Rubaga municipality Kampala, Uganda [24], in which a high clustering rate was reported using IS6110-RFLP genotyping. The differences in clustering rates between the current and former study could be attributed to the high discriminatory power of the 15 loci MIRU-VNTR genotyping panel (HGDI of 0.996).

If true, the possible impact of the presence of low transmission rate, and the implication that most disease in this community could be due to reactivation of MTB infection could be highly influential with regards to infection control measures and disease management.

Table 2 MTB transmission patterns in households

| | | MIRU-VNTR locus ^a | | | | | | | | | | | | | | |
|------------|---|---|----------|----------|----------|----------|----------|---|---|---|---|---|--|--|---|--|
| PT ID | Lineage ^b | 424 | 577 | 580 | 802 | 960 | 1644 | 1955 | 2163b | 2165 | 2401 | 2996 | 3192 | 3690 | 4052 | 4156 |
| 1 -1- 01 | Uganda II | 2 | 5 | 2 | 3 | 3 | 3 | 3 | 2 | 3 | 2 | 4 | 3 | 3 | 7 | 2 |
| 1 -1- 03 | Uganda II | 2 | 5 | 2 | 3 | 3 | 3 | 3 | 2 | 3 | 2 | 4 | 3 | 3 | 7 | 2 |
| 15 -1- 01 | | 3 | 6 | 1 | 3 | 3 | 3 | 3 | 2 | 4 | 2 | 4 | 4 | 3 | 2 | 3 |
| 15 -1 - 03 | | 3 | 6 | 1 | 3 | 3 | 3 | 3 | 2 | 4 | 2 | 4 | 4 | 3 | 2 | 3 |
| 20 -1- 01 | Uganda II | 2 | 5 | 1 | 3 | 3 | 3 | 3 | 2 | 4 | 2 | 5 | 4 | 3 | 4 | 2 |
| 20 -1- 02 | Uganda II | 2 | 5 | 1 | 3 | 3 | 3 | 3 | 2 | 4 | 2 | 5 | 4 | 3 | 4 | 2 |
| 20 -1- 07 | Uganda II | 2 | 5 | 1 | 3 | 3 | 3 | 3 | 2 | 4 | 2 | 5 | 4 | 3 | 4 | 2 |
| 33-1-01 | Uganda II | 2 | 5 | 1 | 3 | 3 | 3 | 3 | 2 | 4 | 2 | 5 | 4 | 3 | 4 | 2 |
| 23 -1- 01 | | 4 | 2 | 2 | 1 | 3 | 1 | 2 | 2 | 4 | 1 | 5 | 3 | 2 | 7 | 2 |
| 23 -1- 03 | | 4 | 3 | 2 | 1 | 3 | 1 | 2 | 2 | 4 | 1 | 5 | 3 | 2 | 7 | 2 |
| 35 -5- 01 | | 2 | 2 | 2 | 3 | 8 | 5 | 4 | 2 | 3 | 4 | 7 | 4 | 3 | 9 | 4 |
| 35 -5- 06 | | 2 | 2 | 2 | 3 | 8 | 5 | 4 | 2 | 3 | 4 | 7 | 4 | 3 | 9 | 4 |
| 36-1-01 | Uganda II | 3 | 4 | 2 | 3 | 2 | 3 | 2 | 3 | 4 | 2 | 4 | 2 | 5 | 8 | 4 |
| 36-1-03 | Uganda II | 3 | 4 | 2 | 3 | 2 | 3 | 2 | 3 | 4 | 2 | 4 | 2 | 5 | 8 | 4 |
| 41 -1- 01 | Uganda I | 2 | 5 | 2 | 3 | 3 | 3 | 2 | 3 | 4 | 2 | 3 | 2 | 3 | 7 | 2 |
| 41 -1- 02 | Uganda I | 2 | 5 | 2 | 3 | 3 | 3 | 2 | 3 | 4 | 2 | 3 | 2 | 3 | 7 | 2 |
| 93-1-01 | Uganda I | 2 | 5 | 2 | 3 | 3 | 3 | 2 | 3 | 4 | 2 | 3 | 2 | 3 | 7 | 2 |
| 100-1-01 | Uganda I | 2 | 5 | 2 | 3 | 3 | 3 | 2 | 3 | 4 | 2 | 3 | 2 | 3 | 7 | 2 |
| 70 -1- 01 | Cameroon | 1 | 5 | 2 | 3 | 3 | 3 | 2 | 4 | 4 | 2 | 5 | 3 | 3 | 5 | 2 |
| 70 -1- 03 | Cameroon | 1 | 5 | 2 | 3 | 3 | 3 | 2 | 4 | 4 | 2 | 5 | 3 | 3 | 5 | 2 |
| | 1 -1- 01 1 -1- 03 15 -1- 01 15 -1 - 03 20 -1- 01 20 -1- 07 33-1-01 23 -1- 01 23 -1- 03 35 -5- 01 36-1-01 36-1-03 41 -1- 01 41 -1- 02 93-1-01 100-1-01 70 -1- 01 | 1 -1- 01 Uganda II 1 -1- 03 Uganda II 15 -1- 01 15 -1 - 03 20 -1- 01 Uganda II 20 -1- 02 Uganda II 20 -1- 07 Uganda II 23 -1- 01 23 -1- 01 23 -1- 03 35 -5- 01 35 -5- 06 36-1-01 Uganda II 41 -1- 01 Uganda II 41 -1- 02 Uganda I 93-1-01 Uganda I 93-1-01 Uganda I 100-1-01 Uganda I 70 -1- 01 Cameroon | 1 -1- 01 | 1 -1- 01 | 1 -1- 01 | 1 -1- 01 | 1 -1- 01 | 1 -1- 01 Uganda II 2 5 2 3 3 1 -1- 03 Uganda II 2 5 2 3 3 15 -1- 01 3 6 1 3 3 15 -1 - 03 3 6 1 3 3 20 -1- 01 Uganda II 2 5 1 3 3 20 -1- 02 Uganda II 2 5 1 3 3 20 -1- 07 Uganda II 2 5 1 3 3 33-1-01 Uganda II 2 5 1 3 3 23 -1- 01 4 2 2 1 3 1 23 -1- 03 4 3 2 1 3 1 35 -5- 01 2 2 2 2 3 8 5 36-1-03 Uganda II 3 4 2 3 2 3 36-1-01 Uganda II 3 4 2 3 2 3 36-1-02 Uganda II 3 4 2 3 2 3 41 -1- 01 Uganda I 2 5 2 3 3 3 | PT ID Lineage ^b 424 577 580 802 960 1644 1955 1 -1- 01 Uganda II 2 5 2 3 3 3 3 1 -1- 03 Uganda II 2 5 2 3 3 3 3 15 -1- 01 3 6 1 3 3 3 3 15 -1- 03 Uganda II 2 5 1 3 3 3 3 20 -1- 01 Uganda II 2 5 1 3 <td>PT ID Lineageb 424 577 580 802 960 1644 1955 2163b 1 -1- 01 Uganda II 2 5 2 3 3 3 2 1 -1- 03 Uganda II 2 5 2 3 3 3 3 2 15 -1- 01 3 6 1 3 3 3 3 2 15 -1 - 03 4 3 6 1 3 3 3 3 2 20 -1- 01 Uganda II 2 5 1 3 3 3 2 20 -1- 02 Uganda II 2 5 1 3 3 3 3 2 20 -1- 07 Uganda II 2 5 1 3 3 3 3 2 33-1-01 Uganda II 2 2 2 1 3 1 2 2 35 -5- 01 2 2</td> <td>PT ID Lineage^b 424 577 580 802 960 1644 1955 2163b 2163b 1 -1- 01 Uganda II 2 5 2 3 3 3 2 3 1 -1- 03 Uganda II 2 5 2 3 3 3 2 4 15 -1- 01 Uganda II 2 5 1 3 3 3 2 4 15 -1- 03 Uganda II 2 5 1 3 3 3 2 4 20 -1- 01 Uganda II 2 5 1 3 3 3 2 4 20 -1- 07 Uganda II 2 5 1 3 3 3 2 4 20 -1- 07 Uganda II 2 5 1 3 3 3 2 4 23 -1- 03 Uganda II 2 2 2 3 8 5 4 <t< td=""><td>PT ID Lineage^b 424 577 580 802 960 1644 1955 2163b 2165 240 1 -1 - 01 Uganda II 2 5 2 3 3 3 2 3 2 1 - 1 - 03 Uganda II 2 5 2 3 3 3 2 3 2 15 - 1 - 01 3 6 1 3 3 3 2 4 2 15 - 1 - 03 Uganda II 2 5 1 3 3 3 2 4 2 15 - 1 - 01 Uganda II 2 5 1 3 3 3 2 4 2 20 - 1 - 01 Uganda II 2 5 1 3 3 3 2 4 2 20 - 1 - 07 Uganda II 2 5 1 3 3 3 3 2 4 2 33 - 1 - 01 <t< td=""><td>PT ID Lineage^b 424 577 580 802 960 1644 1955 2163b 2165 2401 2996 1 -1- 01 Uganda II 2 5 2 3 3 3 2 3 2 4 1 -1- 03 Uganda II 2 5 2 3 3 3 2 3 2 4 15 - 1- 01 3 6 1 3 3 3 3 2 4 2 4 15 - 1- 03 Uganda II 2 5 1 3 3 3 2 4 2 4 20 - 1- 01 Uganda II 2 5 1 3 3 3 2 4 2 5 20 - 1- 02 Uganda II 2 5 1 3 3 3 2 4 2 5 33-1- 01 Uganda II 2 5 1 3 3</td><td>PT ID Lineageb 424 577 580 802 960 1644 1955 2163b 2165 240 2996 3192 1 -1- 01 Uganda II 2 5 2 3 3 3 2 3 2 4 3 1 -1- 03 Uganda II 2 5 2 3 3 3 2 4 2 4 3 15 -1 - 01 3 6 1 3 3 3 2 4 2 4 4 15 - 1 - 03 Uganda II 2 5 1 3 3 3 2 4 2 4 4 20 - 1 - 02 Uganda II 2 5 1 3 3 3 2 4 2 5 4 20 - 1 - 02 Uganda II 2 5 1 3 3 3 2 4 2 5 4 20 - 1 - 07 <</td><td>PT ID Lineage^b 424 577 580 802 960 1644 1955 2163b 2165 2401 2996 3192 3690 1 -1-01 Uganda III 2 5 2 3 3 3 2 3 2 4 3 3 3 1 -1-03 Uganda III 2 5 2 3 3 3 2 4 2 4 3 3 3 3 3 2 4 2 4 4 4 4 3 3 3 3 3 2 4 2 4 4 4 4 3 3 3 3 2 4 2 5 4 3 3 3 3 2 4 2 5 4 3 3 3 3 2 4 2 5 4 3 3 3 3 2 4 2 5</td><td>PT ID Lineage^b 424 577 580 802 960 1644 1955 2163b 2165 2401 2996 3192 3690 4052 1 -1 - 01 Uganda II 2 5 2 3 3 3 2 3 2 4 3 3 7 15 - 1 - 01 3 6 1 3 3 3 3 2 4 3 3 3 7 15 - 1 - 03 3 6 1 3 3 3 3 2 4 2 4 3 3 2 15 - 1 - 03 3 6 1 3 3 3 3 2 4 2 4 4 4 4 3 4 4 2 4 4 2 4 3 4 4 2 4 3 4 4 2 3 4 4 2 3 4</td></t<></td></t<></td> | PT ID Lineageb 424 577 580 802 960 1644 1955 2163b 1 -1- 01 Uganda II 2 5 2 3 3 3 2 1 -1- 03 Uganda II 2 5 2 3 3 3 3 2 15 -1- 01 3 6 1 3 3 3 3 2 15 -1 - 03 4 3 6 1 3 3 3 3 2 20 -1- 01 Uganda II 2 5 1 3 3 3 2 20 -1- 02 Uganda II 2 5 1 3 3 3 3 2 20 -1- 07 Uganda II 2 5 1 3 3 3 3 2 33-1-01 Uganda II 2 2 2 1 3 1 2 2 35 -5- 01 2 2 | PT ID Lineage ^b 424 577 580 802 960 1644 1955 2163b 2163b 1 -1- 01 Uganda II 2 5 2 3 3 3 2 3 1 -1- 03 Uganda II 2 5 2 3 3 3 2 4 15 -1- 01 Uganda II 2 5 1 3 3 3 2 4 15 -1- 03 Uganda II 2 5 1 3 3 3 2 4 20 -1- 01 Uganda II 2 5 1 3 3 3 2 4 20 -1- 07 Uganda II 2 5 1 3 3 3 2 4 20 -1- 07 Uganda II 2 5 1 3 3 3 2 4 23 -1- 03 Uganda II 2 2 2 3 8 5 4 <t< td=""><td>PT ID Lineage^b 424 577 580 802 960 1644 1955 2163b 2165 240 1 -1 - 01 Uganda II 2 5 2 3 3 3 2 3 2 1 - 1 - 03 Uganda II 2 5 2 3 3 3 2 3 2 15 - 1 - 01 3 6 1 3 3 3 2 4 2 15 - 1 - 03 Uganda II 2 5 1 3 3 3 2 4 2 15 - 1 - 01 Uganda II 2 5 1 3 3 3 2 4 2 20 - 1 - 01 Uganda II 2 5 1 3 3 3 2 4 2 20 - 1 - 07 Uganda II 2 5 1 3 3 3 3 2 4 2 33 - 1 - 01 <t< td=""><td>PT ID Lineage^b 424 577 580 802 960 1644 1955 2163b 2165 2401 2996 1 -1- 01 Uganda II 2 5 2 3 3 3 2 3 2 4 1 -1- 03 Uganda II 2 5 2 3 3 3 2 3 2 4 15 - 1- 01 3 6 1 3 3 3 3 2 4 2 4 15 - 1- 03 Uganda II 2 5 1 3 3 3 2 4 2 4 20 - 1- 01 Uganda II 2 5 1 3 3 3 2 4 2 5 20 - 1- 02 Uganda II 2 5 1 3 3 3 2 4 2 5 33-1- 01 Uganda II 2 5 1 3 3</td><td>PT ID Lineageb 424 577 580 802 960 1644 1955 2163b 2165 240 2996 3192 1 -1- 01 Uganda II 2 5 2 3 3 3 2 3 2 4 3 1 -1- 03 Uganda II 2 5 2 3 3 3 2 4 2 4 3 15 -1 - 01 3 6 1 3 3 3 2 4 2 4 4 15 - 1 - 03 Uganda II 2 5 1 3 3 3 2 4 2 4 4 20 - 1 - 02 Uganda II 2 5 1 3 3 3 2 4 2 5 4 20 - 1 - 02 Uganda II 2 5 1 3 3 3 2 4 2 5 4 20 - 1 - 07 <</td><td>PT ID Lineage^b 424 577 580 802 960 1644 1955 2163b 2165 2401 2996 3192 3690 1 -1-01 Uganda III 2 5 2 3 3 3 2 3 2 4 3 3 3 1 -1-03 Uganda III 2 5 2 3 3 3 2 4 2 4 3 3 3 3 3 2 4 2 4 4 4 4 3 3 3 3 3 2 4 2 4 4 4 4 3 3 3 3 2 4 2 5 4 3 3 3 3 2 4 2 5 4 3 3 3 3 2 4 2 5 4 3 3 3 3 2 4 2 5</td><td>PT ID Lineage^b 424 577 580 802 960 1644 1955 2163b 2165 2401 2996 3192 3690 4052 1 -1 - 01 Uganda II 2 5 2 3 3 3 2 3 2 4 3 3 7 15 - 1 - 01 3 6 1 3 3 3 3 2 4 3 3 3 7 15 - 1 - 03 3 6 1 3 3 3 3 2 4 2 4 3 3 2 15 - 1 - 03 3 6 1 3 3 3 3 2 4 2 4 4 4 4 3 4 4 2 4 4 2 4 3 4 4 2 4 3 4 4 2 3 4 4 2 3 4</td></t<></td></t<> | PT ID Lineage ^b 424 577 580 802 960 1644 1955 2163b 2165 240 1 -1 - 01 Uganda II 2 5 2 3 3 3 2 3 2 1 - 1 - 03 Uganda II 2 5 2 3 3 3 2 3 2 15 - 1 - 01 3 6 1 3 3 3 2 4 2 15 - 1 - 03 Uganda II 2 5 1 3 3 3 2 4 2 15 - 1 - 01 Uganda II 2 5 1 3 3 3 2 4 2 20 - 1 - 01 Uganda II 2 5 1 3 3 3 2 4 2 20 - 1 - 07 Uganda II 2 5 1 3 3 3 3 2 4 2 33 - 1 - 01 <t< td=""><td>PT ID Lineage^b 424 577 580 802 960 1644 1955 2163b 2165 2401 2996 1 -1- 01 Uganda II 2 5 2 3 3 3 2 3 2 4 1 -1- 03 Uganda II 2 5 2 3 3 3 2 3 2 4 15 - 1- 01 3 6 1 3 3 3 3 2 4 2 4 15 - 1- 03 Uganda II 2 5 1 3 3 3 2 4 2 4 20 - 1- 01 Uganda II 2 5 1 3 3 3 2 4 2 5 20 - 1- 02 Uganda II 2 5 1 3 3 3 2 4 2 5 33-1- 01 Uganda II 2 5 1 3 3</td><td>PT ID Lineageb 424 577 580 802 960 1644 1955 2163b 2165 240 2996 3192 1 -1- 01 Uganda II 2 5 2 3 3 3 2 3 2 4 3 1 -1- 03 Uganda II 2 5 2 3 3 3 2 4 2 4 3 15 -1 - 01 3 6 1 3 3 3 2 4 2 4 4 15 - 1 - 03 Uganda II 2 5 1 3 3 3 2 4 2 4 4 20 - 1 - 02 Uganda II 2 5 1 3 3 3 2 4 2 5 4 20 - 1 - 02 Uganda II 2 5 1 3 3 3 2 4 2 5 4 20 - 1 - 07 <</td><td>PT ID Lineage^b 424 577 580 802 960 1644 1955 2163b 2165 2401 2996 3192 3690 1 -1-01 Uganda III 2 5 2 3 3 3 2 3 2 4 3 3 3 1 -1-03 Uganda III 2 5 2 3 3 3 2 4 2 4 3 3 3 3 3 2 4 2 4 4 4 4 3 3 3 3 3 2 4 2 4 4 4 4 3 3 3 3 2 4 2 5 4 3 3 3 3 2 4 2 5 4 3 3 3 3 2 4 2 5 4 3 3 3 3 2 4 2 5</td><td>PT ID Lineage^b 424 577 580 802 960 1644 1955 2163b 2165 2401 2996 3192 3690 4052 1 -1 - 01 Uganda II 2 5 2 3 3 3 2 3 2 4 3 3 7 15 - 1 - 01 3 6 1 3 3 3 3 2 4 3 3 3 7 15 - 1 - 03 3 6 1 3 3 3 3 2 4 2 4 3 3 2 15 - 1 - 03 3 6 1 3 3 3 3 2 4 2 4 4 4 4 3 4 4 2 4 4 2 4 3 4 4 2 4 3 4 4 2 3 4 4 2 3 4</td></t<> | PT ID Lineage ^b 424 577 580 802 960 1644 1955 2163b 2165 2401 2996 1 -1- 01 Uganda II 2 5 2 3 3 3 2 3 2 4 1 -1- 03 Uganda II 2 5 2 3 3 3 2 3 2 4 15 - 1- 01 3 6 1 3 3 3 3 2 4 2 4 15 - 1- 03 Uganda II 2 5 1 3 3 3 2 4 2 4 20 - 1- 01 Uganda II 2 5 1 3 3 3 2 4 2 5 20 - 1- 02 Uganda II 2 5 1 3 3 3 2 4 2 5 33-1- 01 Uganda II 2 5 1 3 3 | PT ID Lineageb 424 577 580 802 960 1644 1955 2163b 2165 240 2996 3192 1 -1- 01 Uganda II 2 5 2 3 3 3 2 3 2 4 3 1 -1- 03 Uganda II 2 5 2 3 3 3 2 4 2 4 3 15 -1 - 01 3 6 1 3 3 3 2 4 2 4 4 15 - 1 - 03 Uganda II 2 5 1 3 3 3 2 4 2 4 4 20 - 1 - 02 Uganda II 2 5 1 3 3 3 2 4 2 5 4 20 - 1 - 02 Uganda II 2 5 1 3 3 3 2 4 2 5 4 20 - 1 - 07 < | PT ID Lineage ^b 424 577 580 802 960 1644 1955 2163b 2165 2401 2996 3192 3690 1 -1-01 Uganda III 2 5 2 3 3 3 2 3 2 4 3 3 3 1 -1-03 Uganda III 2 5 2 3 3 3 2 4 2 4 3 3 3 3 3 2 4 2 4 4 4 4 3 3 3 3 3 2 4 2 4 4 4 4 3 3 3 3 2 4 2 5 4 3 3 3 3 2 4 2 5 4 3 3 3 3 2 4 2 5 4 3 3 3 3 2 4 2 5 | PT ID Lineage ^b 424 577 580 802 960 1644 1955 2163b 2165 2401 2996 3192 3690 4052 1 -1 - 01 Uganda II 2 5 2 3 3 3 2 3 2 4 3 3 7 15 - 1 - 01 3 6 1 3 3 3 3 2 4 3 3 3 7 15 - 1 - 03 3 6 1 3 3 3 3 2 4 2 4 3 3 2 15 - 1 - 03 3 6 1 3 3 3 3 2 4 2 4 4 4 4 3 4 4 2 4 4 2 4 3 4 4 2 4 3 4 4 2 3 4 4 2 3 4 |

^aThe numerical figures refer to the number of alleles per PCR-amplified MIRU-VNTR locus [8,17].

^bBlanks for K, M and N indicate unique strains i.e., those without matching strain in the database. Letters in parenthesis [(J), (K), (L), (M), (N), (O), (P) and (Q)] represent households.

Figures under PTID (Patient Identification) column refer to the index cases (ending with 1, e.g., 1-1-01) and contact cases (ending with a numerical value > 1, e.g., 1-1-03). For (L) and (P), a similar strain was transmitted to patients in other households.

Probably in future, treatment of latent MTB infections should be considered as a control strategy in high endemic areas as it is in industrialized settings. Nevertheless, TB transmission could still be high in Kawempe municipality; the fact that this study only looked at one culture sample per patient, more samples from more households (and more genotyping methods done on each sample) will be needed for conclusive findings.

Six clusters (2, 5, 6, 9, 12 and 15, see Figure 1), each with two isolates (12 isolates in total) involved members of the same household, implying possible household transmission. Two clusters (4 and 10, see Figure 1), each with four isolates, involved participants within the same household and those outside the household (implying a common strain among them). Seven clusters (1, 7, 8, 11, 13, 14 and 15, see Figure 1), each with two isolates, were from epidemiologically unlinked participants. Recent transmission of PTB was found in only 17 patients (15%) who had epidemiologically linked strains. Overall, 17 households had patients with similar strains but the corresponding cultures for 10 index cases were missing. Eight households had similar MTB strains for both index and contact cases, indicating possible transmission (see Table 2). However, household transmission could be higher than we are reporting if the index cases for the other contacts were available.

Conclusion

MIRU-VNTR genotyping revealed low clustering and high diversity of MTB strains in Kawempe municipality and confirmed earlier reports that MTB strain "Uganda genotype" is the predominant lineage in Kampala, Uganda. MIRU-VNTR typing with a panel of 15 loci is applicable in a Ugandan setting, and can unravel clonally complex strains into individual strains. A nation-wide study to determine the full spectrum of circulating MTB strains in Uganda will be helpful.

Additional material

Additional file 1: MTB strain types with reference to the MIRU-VNTRplus database. Highlighted yellow are the households where transmission was predicted. Patients with mixed infections are highlighted in grey. ^aPTID (Patient Identification); index cases end with 1 (e.g., 1-1-01) while contact cases end with a numerical value > 1 (e.g., 1-1-03). ^bBlanks refer to unique strains i.e., those without a matching strain in the database. ^cThe numerical figures refer to the number of alleles per PCR-amplified MIRU-VNTR locus [8,17].

Abbreviations

MIRU-VNTR: mycobacterial interspersed repetitive units - variable number of tandem repeats; HGDI: Hunter Gaston Discriminatory Index.

Acknowledgements and Funding

P. Supply for access to the technical guide for MIRU-VNTR genotyping. Gratitude to Dr. S. Zalwango; the staff at the TB wards of Mulago Hospital Complex, Kampala, Uganda; the TB laboratory team at the JCRC, Kampala; and Ms Geraldine Nalwadda (Molecular Biology laboratory). This study was supported in part by the Howard Hughes Medical Institute Student Research Fellowship and the University of Pittsburgh Student Global Travel Grant to KRD; the AIDS International Training and Research Program at Case Western Reserve University, Grant #D43-TW000011; the Tuberculosis Research Unit, established with Federal funds from the United Sates National Institutes of Allergy and Infectious Diseases & the United States National Institutes of Health and Human Services, under Contract Nos. NO1-Al-95383 and HHSN266200700022C/NO1-Al-70022; and the National Institutes of Health Grants (R01 Al075637-01 & SRO1A1075637-4). DPK was supported by the Fogarty International Center training support (award #U2RTW006879) through the Clinical Operational & Health Services Research (COHRE) Training program at the Joint Clinical Research Center, Kampala, Uganda.

We thank Dr. I.C. Shamputa and Dr. C. Barry for technical assistance, and Dr.

Author details

¹Department of Medical Microbiology, School of Biomedical Sciences, Makerere University College of Health Sciences, Kampala, Uganda. ²Epidemiology and Biostatistics, College of Public Health, University of Georgia, Athens, USA. ³Department of Pediatrics, Boston Medical Center, Boston University, Boston, USA.

Authors' contributions

LN and KRD carried out the experimental procedures. LN, DPK, FAK and PRO analyzed the data. DPK wrote the manuscript. KRD, CCW and MLJ conceived the study, participated in its design and coordination and proofread the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 3 May 2011 Accepted: 11 August 2011 Published: 11 August 2011

References

- World Health Organisation: Global tuberculosis control: a short update to the 2009 report. [http://www.who.int/tb/publications/global_report/ 2009/update/en/index.html].
- Allix-Beguec C, Harmsen D, Weniger T, Supply P, Niemann S: Evaluation and Strategy for Use of MIRU-VNTRplus, a Multifunctional Database for Online Analysis of Genotyping Data and Phylogenetic Identification of Mycobacterium tuberculosis Complex Isolates. J Clin Microbiol 2008, 46(8):2692-2699.
- Tuberculosis Profile for Uganda USAID. [http://www.usaid.gov/our_work/ global_health/id/tuberculosis/countries/africa/uganda.pdf].
- Guwatudde D, Zalwango S, Kamya MR, Debanne SM, Diaz MI, Okwera A, Mugerwa RD, King C, Whalen CC: Burden of tuberculosis in Kampala, Uganda. Bull World Health Organ 2003, 81(11):799-805.
- Rovina N, Karabela S, Constantoulakis P, Michou V, Konstantinou K, Sgountzos V, Roussos C, Poulakis N: MIRU-VNTR typing of drug-resistant tuberculosis isolates in Greece. Therapeutic Advances in Respiratory Disease 2011
- Mathema B, Kurepina NE, Bifani PJ, Kreiswirth BN: Molecular Epidemiology of Tuberculosis: Current Insights. Clin Microbiol Rev 2006, 19(4):658-685.
- Stavrum R, Mphahlele M, Ovreas K, Muthivhi T, Fourie PB, Weyer K, Grewal HM: High diversity of Mycobacterium tuberculosis genotypes in South Africa and preponderance of mixed infections among ST53 isolates. J Clin Microbiol 2009, 47(6):1848-1856.
- Supply P, Allix C, Lesjean S, Cardoso-Oelemann M, Rusch-Gerdes S, Willery E, Savine E, de Haas P, van Deutekom H, Roring S, et al: Proposal for Standardization of Optimized Mycobacterial Interspersed Repetitive Unit-Variable-Number Tandem Repeat Typing of Mycobacterium tuberculosis. J Clin Microbiol 2006, 44(12):4498-4510.
- Alonso-Rodriguez N, Martinez-Lirola M, Herranz M, Sanchez-Benitez M, Barroso P, group I-T, Bouza E, de Viedma D: Evaluation of the new advanced 15-loci MIRU-VNTR genotyping tool in Mycobacterium

- tuberculosis molecular epidemiology studies. *BMC Microbiology* 2008, 8(1):34.
- Wang J, Liu Y, Zhang CL, Ji BY, Zhang LZ, Shao YZ, Jiang SL, Suzuki Y, Nakajima C, Fan CL, et al: Genotypes and Characteristics of Clustering and Drug Susceptibility of Mycobacterium tuberculosis Isolates Collected in Heilongjiang Province, China. J Clin Microbiol 49(4):1354-1362.
- Dickman KR, Nabyonga L, Kateete DP, Katabazi FA, Asiimwe BB, Mayanja HK, Okwera A, Whalen C, Joloba ML: Detection of multiple strains of Mycobacterium tuberculosis using MIRU-VNTR in patients with pulmonary tuberculosis in Kampala, Uganda. BMC Infect Dis 10:349.
- Whalen CC, Zalwango S, Chiunda A, Malone L, Eisenach K, Joloba M, Boom WH, Mugerwa R: Secondary Attack Rate of Tuberculosis in Urban Households in Kampala, Uganda. PLoS ONE 2011, 6(2):e16137.
- Mudido PM, Guwatudde D, Nakakeeto MK, Bukenya GB, Nsamba D, Johnson JL, Mugerwa RD, Ellner JJ, Whalen CC: The effect of bacille Calmette-Guerin vaccination at birth on tuberculin skin test reactivity in Ugandan children. Int J Tuberc Lung Dis 1999, 3(10):891-895.
- Whalen CC, Chiunda A, Zalwango S, Nshuti L, Jones-Lopez E, Okwera A, Hirsch C, Peters P, Boom WH, Mugerwa RD: Immune correlates of acute Mycobacterium tuberculosis infection in household contacts in Kampala, Uganda. Am J Trop Med Hyg 2006, 75(1):55-61.
- Guwatudde D, Nakakeeto M, Jones-Lopez EC, Maganda A, Chiunda A, Mugerwa RD, Ellner JJ, Bukenya G, Whalen CC: Tuberculosis in Household Contacts of Infectious Cases in Kampala, Uganda. Am J Epidemiol 2003, 158(9):887-898.
- Muhumuza J, Asiimwe BB, Kayes S, Mugyenyi R, Whalen C, Mugerwa RD, Boom H, Eisenach KD, Joloba ML: Introduction of an in-house PCR for routine identification of M. tuberculosis in a low-income country. Int J Tuberc Lung Dis 2006, 10(11):1262-1267.
- Multilocus Variable Number Tandem Repeat Genotyping of MIRU-VNTRplus.
- Tazi L, Reintjes R, Banuls AL: Tuberculosis transmission in a high incidence area: a retrospective molecular epidemiological study of Mycobacterium tuberculosis in Casablanca, Morocco. Infect Genet Evol 2007, 7(5):636-644.
- Hunter PR, Gaston MA: Numerical index of the discriminatory ability of typing systems: an application of Simpson's index of diversity. J Clin Microbiol 1988, 26(11):2465-2466.
- Benon BAsiimwe, S G, Gunilla Kallenius, Koivula Tuija, Moses LJoloba: Mycobacterium tuberculosis spoligotypes and drug susceptibility pattern of isolates from tuberculosis patients in peri-urban Kampala, Uganda. BMC Infectious Diseases 2008, 8(101):1471-2334.
- Asiimwe BB, Koivula T, Kallenius G, Huard RC, Ghebremichael S, Asiimwe J, Joloba ML: Mycobacterium tuberculosis Uganda genotype is the predominant cause of TB in Kampala, Uganda. Int J Tuberc Lung Dis 2008, 12(4):386-391.
- Mulenga C, Shamputa IC, Mwakazanga D, Kapata N, Portaels F, Rigouts L: Diversity of Mycobacterium tuberculosis genotypes circulating in Ndola, Zambia. BMC Infect Dis 2010, 10:177.
- Gagneux S, Burgos MV, DeRiemer K, Encisco A, Munoz S, Hopewell PC, Small PM, Pym AS: Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PLoS Pathog 2006, 2(6): e61.
- Asiimwe B, Joloba M, Ghebremichael S, Koivula T, Kateete D, Katabazi F, Pennhag A, Petersson R, Kallenius G: DNA restriction fragment length polymorphism analysis of Mycobacterium tuberculosis isolates from HIVseropositive and HIV-seronegative patients in Kampala, Uganda. BMC Infectious Diseases 2009, 9(1):12.

doi:10.1186/1756-0500-4-280

Cite this article as: Nabyonga et al.: Determination of circulating Mycobacterium tuberculosis strains and transmission patterns among pulmonary TB patients in Kawempe municipality, Uganda, using MIRU-VNTR. BMC Research Notes 2011 4:280.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

